Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer
✍ Scribed by Scott Wadler, Laura Tenteromano, Lorraine Cazenave…
- Book ID
- 120777280
- Publisher
- Springer
- Year
- 1994
- Tongue
- English
- Weight
- 729 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m 2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin
Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were ach